Drugmaker partners Organon and
Samsung Bioepis said on Saturday that they had launched a far
cheaper copycat version of AbbVie s blockbuster
arthritis drug Humira, while another drugmaker entered.
A California federal judge on Wednesday agreed to ship back to state court allegations that CVS Caremark and Express Scripts conspired to hike insulin drug prices, finding that the state of California's claims do not relate to the companies' work with the federal government.
At least four drugmakers are expected to launch new copycat versions of AbbVie's top-selling rheumatoid arthritis drug, Humira, over the next week, but experts expect little change in prices for the treatment even with the new competition. Drugmakers Boehringer Ingelheim, Sandoz and Organon are expected to launch their biosimilars on Saturday, adding to U.S. competition for the drug that started when Amgen released its copy in January. Usually prices fall, often dramatically, when multiple generic versions of a widely used medication enter market.